67 related articles for article (PubMed ID: 4038381)
1. Comparative activity and distribution studies of five platinum analogues in nude mice bearing human ovarian carcinoma xenografts.
Boven E; van der Vijgh WJ; Nauta MM; Schlüper HM; Pinedo HM
Cancer Res; 1985 Jan; 45(1):86-90. PubMed ID: 4038381
[TBL] [Abstract][Full Text] [Related]
2. The Synergistic Effect of Hyperthermia and Chemotherapy in Magnetite Nanomedicine-Based Lung Cancer Treatment.
Yang SJ; Huang CH; Wang CH; Shieh MJ; Chen KC
Int J Nanomedicine; 2020; 15():10331-10347. PubMed ID: 33376324
[TBL] [Abstract][Full Text] [Related]
3. The anti-malarial drug atovaquone potentiates platinum-mediated cancer cell death by increasing oxidative stress.
Coates JTT; Rodriguez-Berriguete G; Puliyadi R; Ashton T; Prevo R; Wing A; Granata G; Pirovano G; McKenna GW; Higgins GS
Cell Death Discov; 2020; 6():110. PubMed ID: 33133645
[TBL] [Abstract][Full Text] [Related]
4. Reduced accumulation of platinum drugs is not observed in drug-resistant ovarian cancer cell lines derived from cisplatin-treated patients.
Stukova M; Hall MD; Tsotsoros SD; Madigan JP; Farrell NP; Gottesman MM
J Inorg Biochem; 2015 Aug; 149():45-8. PubMed ID: 26021697
[TBL] [Abstract][Full Text] [Related]
5. UCHL1 Is a Putative Tumor Suppressor in Ovarian Cancer Cells and Contributes to Cisplatin Resistance.
Jin C; Yu W; Lou X; Zhou F; Han X; Zhao N; Lin B
J Cancer; 2013; 4(8):662-70. PubMed ID: 24155778
[TBL] [Abstract][Full Text] [Related]
6. Proteomic approaches in understanding action mechanisms of metal-based anticancer drugs.
Wang Y; Chiu JF
Met Based Drugs; 2008; 2008():716329. PubMed ID: 18670610
[TBL] [Abstract][Full Text] [Related]
7. Toxicity and cerebrospinal fluid levels of carboplatin chronically infused into the brainstem of a primate.
Strege RJ; Liu YJ; Kiely A; Johnson RM; Gillis EM; Storm P; Carson BS; Jallo GI; Guarnieri M
J Neurooncol; 2004 May; 67(3):327-34. PubMed ID: 15164988
[TBL] [Abstract][Full Text] [Related]
8. Influence of single and multiple doses of amifostine on the efficacy and the pharmacokinetics of carboplatin in mice.
Korst AE; Boven E; van der Sterre ML; Fichtinger-Schepman AM; van der Vijgh WJ
Br J Cancer; 1997; 75(10):1439-46. PubMed ID: 9166935
[TBL] [Abstract][Full Text] [Related]
9. The development of a novel immunotherapy model of human ovarian cancer in human PBL-severe combined immunodeficient (SCID) mice.
Walker W; Gallagher G
Clin Exp Immunol; 1995 Sep; 101(3):494-501. PubMed ID: 7664496
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics and tissue distribution of cisplatin in nude mice: platinum levels and cisplatin-DNA adducts.
Johnsson A; Olsson C; Nygren O; Nilsson M; Seiving B; Cavallin-Stahl E
Cancer Chemother Pharmacol; 1995; 37(1-2):23-31. PubMed ID: 7497593
[TBL] [Abstract][Full Text] [Related]
11. Development of new anti-cancer drugs.
Pinedo HM
Med Oncol Tumor Pharmacother; 1986; 3(2):63-9. PubMed ID: 3747638
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of ethylenediaminemalonatoplatinum(II) (JM-40) during phase I trial.
Elferink F; van der Vijgh WJ; ten Bokkel Huinink WW; Vermorken JB; Klein I; Winograd B; Knobf MK; Simonetti G; Gall HE; McVie JG
Br J Cancer; 1987 Oct; 56(4):479-83. PubMed ID: 3689665
[TBL] [Abstract][Full Text] [Related]
13. Absolute and relative activities of platinum-complexes on human tumors as evaluated by an antimetabolic in vitro assay.
Daidone MG; Silvestrini R; Zaffaroni N; Grignolio E; Landoni F
Invest New Drugs; 1987; 5(3):245-50. PubMed ID: 3312080
[TBL] [Abstract][Full Text] [Related]
14. In vitro chemosensitivity of brain tumors to cisplatin and its analogues, iproplatin and carboplatin.
Dodion P; Sanders C; Georges P; Kenis Y
Cancer Chemother Pharmacol; 1988; 22(1):80-2. PubMed ID: 3293841
[TBL] [Abstract][Full Text] [Related]
15. Advances in platinum cancer chemotherapy. Advances in the design of cisplatin analogues.
Hydes PC; Russell MJ
Cancer Metastasis Rev; 1988 Apr; 7(1):67-89. PubMed ID: 3293834
[TBL] [Abstract][Full Text] [Related]
16. Superior efficacy of trimelamol to hexamethylmelamine in human ovarian cancer xenografts.
Boven E; Nauta MM; Schlüper HM; Erkelens CA; Pinedo HM
Cancer Chemother Pharmacol; 1986; 18(2):124-8. PubMed ID: 3098444
[TBL] [Abstract][Full Text] [Related]
17. Enhanced transplantability of human ovarian cancer lines in cyclophosphamide-pretreated nude mice.
Nauta MM; Boven E; Schlüper HM; Erkelens CA; Pinedo HM
Br J Cancer; 1986 Aug; 54(2):331-5. PubMed ID: 3017398
[No Abstract] [Full Text] [Related]
18. Cisplatin/carboplatin cross-resistance in ovarian cancer.
Gore ME; Fryatt I; Wiltshaw E; Dawson T; Robinson BA; Calvert AH
Br J Cancer; 1989 Nov; 60(5):767-9. PubMed ID: 2803953
[TBL] [Abstract][Full Text] [Related]
19. Carboplatin. A preliminary review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the treatment of cancer.
Wagstaff AJ; Ward A; Benfield P; Heel RC
Drugs; 1989 Feb; 37(2):162-90. PubMed ID: 2649354
[TBL] [Abstract][Full Text] [Related]
20. Complete remission of brain metastases of ovarian cancer following high-dose carboplatin: a case report and pharmacokinetic study.
Vlasveld LT; Beynen JH; Boogerd W; Ten Bokkel Huinink WW; Rodenhuis S
Cancer Chemother Pharmacol; 1990; 25(5):382-3. PubMed ID: 2407368
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
